Product | Indication | Preclinical | Phase One | Phase Two | Phase Three | Commercial Rights |
Retinal Disease Programs | ||||||
KIO-301 (Intravitreal) | Retinitis Pigmentosa (Mutation Agnostic) |
|
|
|
|
Théa Open Innovation (global less Asia) |
Choroideremia |
|
|
|
|
||
Stargardt Disease |
|
|
|
|
||
KIO-104 (Intravitreal) | Retinal Inflammation |
|
|
|
|
Kiora Pharmaceuticals |
Proliferative Vitreoretinopathy |
|